Link Pharmacy, sued by Novo Nordisk in the Northern District of Texas for marketing non-FDA approved compounded semaglutide, filed a disclosure statement listing OpenLoop Health Inc
Clinical priorities may include weight loss, avoidance of hypoglycemia, desired magnitude of glucose lowering, cost, side-effect profile, possibility of pregnancy, and comorbidities [Grade D, Consensus]
So hopefully they clean up their act now that theyve been caught red handed more than once
These benefits stem from tirzepatide dual GIP/GLP-1 mechanism affecting receptors throughout the body
Protecting muscle and bone density is a long-term need, not something that resolves once initial weight loss goals are met, so a protein-first approach is worth maintaining well past the early phase of treatment.
A narrative review published in Cureus searched PubMed, Embase, and Scopus through August 2025, examining the intersection of GLP-1 therapy and autoimmune thyroid disease